key: cord-0998175-o83yo7li authors: Raj, Revathi; Uppuluri, Ramya; Parambil, Badira; Dhariwal, Nidhi; Totadri, Sidharth; Mathew, Leni Grace; Radhakrishnan, Venkatraman; Charan, Abishek; Yadav, Satya Prakash; Mahajan, Amita; Mudaliar, Sangeeta; Sharma, Ratna; Manglani, Mamta; Kharya, Gaurav; Verma, Nishant; Arora, Ramandeep; Ghara, Niharendu; Ks, Reghu; Radhakrishnan, Nita; Iyer, Nisha; Mehta, Priti; Singh, Amitabh; Patel, Shivani; John, Joseph; Bhat, Sunil; Badiger, Shobha; Siddaiahgari, Sirisharani; Kakkar, Shruti; Scott, Julius; Jayaraman, Dhaarani; Srinivasan, Arathi; Krishnan, Yamini; Sonamani, Ngangbam; Misra, Ruchira; Bafna, Vibha; Seth, Rachna; Kutty, Purvi Kadakia; Kanakia, Swati; Rao, Vasudha; Prakash, Anand; Bharadwaj, Vandana; Chinnasamy, Girish title: Outcomes of COVID-19 in children with cancer – Report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India date: 2022-03-15 journal: Pediatric Hematology Oncology Journal DOI: 10.1016/j.phoj.2022.03.002 sha: 7618b69eefe0e2c1ad90505891c749d7369c62f7 doc_id: 998175 cord_uid: o83yo7li Introduction The clinical outcomes of COVID-19 infection in children with cancer have been variable worldwide. Therefore, we aimed to collect data from all regions in India through a national collaborative study and identify factors that cause mortality directly related to COVID-19 infection. Methods Data was collected prospectively on children across India on cancer therapy and diagnosed with COVID-19 infections from 47 centers from April 2020 to October 2021. Information was recorded on the demographics, the number of children that required intervention, and the outcome of the infection. In addition, we analyzed the impact of the delta variant in 2021. Results A total of 659 children were studied, of whom 64% were male and 36% were female. The data from the eastern region was sparse, and this was a collection bias. COVID-19 infection was predominantly seen in children less than five years. The delta variant had a higher impact in the southern region, and this was statistically significant. Of the 659 children, 30 children died (4.5%), however only 7 of the deaths were directly attributed to COVID-19 infection (1%). Conclusion The study reports the largest nationally representative cohort of children with cancer and COVID-19 to date in India. We identified demographic and clinical factors associated with increased all-cause mortality in patients with cancer. Complete characterization of the cohort has provided further insights into the effects of COVID-19 on cancer outcomes. The low mortality allows us to recommend that specific cancer treatments be continued without delays in therapy. The clinical outcomes of COVID-19 infection in children with cancer have been variable worldwide. Therefore, we aimed to collect data from all regions in India through a national collaborative study and identify factors that cause mortality directly related to COVID-19 infection. Data was collected prospectively on children across India on cancer therapy and diagnosed with COVID-19 infections from 47 centers from April 2020 to October 2021. Information was recorded on the demographics, the number of children that required intervention, and the outcome of the infection. In addition, we analyzed the impact of the delta variant in 2021. A total of 659 children were studied, of whom 64% were male and 36% were female. The data from the eastern region was sparse, and this was a collection bias. COVID-19 infection was predominantly seen in children less than five years. The delta variant had a higher impact in the southern region, and this was statistically significant. Of the 659 children, 30 children died (4.5%), however only 7 of the deaths were directly attributed to COVID-19 infection (1%). Introduction COVID-19 has had a significant impact on cancer services across the world. The pandemic has resulted in delayed diagnosis, therapy interruptions, and considerable morbidity and mortality. The most recent COVID-19 and Cancer Consortium (CCC-19) found a 28% increased risk of COVID-19 severity and 61% increased risk of 30-day mortality with cytotoxic agents 1 . Specific therapies such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, platinum-etoposide, and DNA methyltransferase inhibitors were associated with increased 30day all-cause mortality. In contrast, the UK Coronavirus Cancer Monitoring Project did not find an increased risk of death with immunotherapies, targeted therapies, and hormone therapies after adjusting for age, sex, and comorbidities 2, 3 . However, real world data was required to analyze the effects of COVID-19 in children undergoing cancer therapy. In April 2020, the Indian Pediatric Oncology Group (InPOG) helped establish the COVID-19 registry for all physicians to report minimal outcome data across the country. The registry captured multicenter outcome data from India, including patients from the first wave in 2020 and the delta variant seen during the second wave in 2021.The latter was reported to be more virulent resulting in a higher mortality 5 . The study collected prospective data on children diagnosed with COVID-19 infection between April 14th, 2020, to October 14th, 2021, for 18 months across a total of 47 centers in India. All centers had obtained clearance from their ethical committee, and the data was accrued using a Google form with regular reminders set for uploading the data. The minimal data set included the age and sex of the child, the region from Indianorth, south, east, or west and the initial diagnosis of hematolymphoid or a solid tumor. All children included had a confirmed RT PCR for the SARS COVID-19 virus. We collected data on the need for intervention with paracetamol, antihistamines, and hospitalization for COVID-19 infection. Interventions for active disease included steroids, oxygen, ventilation, remdesivir, and anticoagulation. The outcome of the event and information on direct deaths due to COVID-19 infections were collected. Data analysis was performed using the SPSS software. The study has been approved by the institutional review board and written informed consent was obtained from parents of all children. We collected data on a total of 659 children with a median age of 7 years, number of males being 419 (63.5%) and females being 240 (36.4%), with a male-female ratio of 1.7:1. The initial peak incidence was in May 2020, and the second wave due to the delta variant occurred in May 2021. The experience during the first wave helped cancer services across the country prepare better for the second wave. Aggressive testing, reducing hospital visits, avoiding visitors during an J o u r n a l P r e -p r o o f inpatient stay, teleconsultation, home testing, and published guidelines for care ensured that the mortality was kept low even during the emergence of the Delta variant 11 . In addition, the registry helped connect physicians across the country to share experiences and provide optimal care. The main drawback of this registry data is the lack of comprehensive data as we failed to capture all children with cancer diagnosed with COVID-19 infection. Most physicians were posted as frontline workers and most cancer centers did not have a dedicated data manager resulting in a reporting bias. The more significant effect of COVID-19 in India is already seen in our services across the country as the number of relapses in all curable childhood cancers is on the increase as there have been interruptions in therapy for several patients 12 . In addition, rigid lockdowns, lack of healthcare workers, loss of jobs, and financial constraints have resulted in suboptimal care. Collateral damage in terms of challenges in the delivery of care has thus been more evident than the direct impact of COVID-19 in children with cancer. The InPOGCOVID-19 registry data has tracked the incidence of the infection during 2020 and 2021 and recorded data on a total of 659 children. There is a preponderance of male children (63.5%) and children less than five years (42%) and a diagnosis of leukemia and lymphoma in the registry (73.4%). The first wave affected the northern and western parts of the country, while the second wave had a higher impact in the southern regions. The direct COVID-19 related mortality was low at 1%, and less than one-third of the cohort required intervention. This data will help health care providers across our country improve services and optimize care during crises so that children with cancer can access seamless care in the future. J o u r n a l P r e -p r o o f ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. Cancer Cell COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study United Kingdom Paediatric Coronavirus Cancer Monitoring Project Guidelines for the management of COVID 19 in children below 18 years. Ministry of Health and Family Welfare. Guidelinesfor the ManagementofCOVID-19 in children The biological and clinical significance of emerging SARS-CoV-2 variants COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell, and solid organ transplant patients The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine receptor system COVID-19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GET ON/GETH). Pediatr Blood Cancer Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region Morbidity of pandemic H1N1 influenza in children with cancer. Pediatr Blood Cancer .617.2 Delta variant replication and immune evasion The impact of COVID-19 pandemic on access to treatment for children with cancer in India and treating center practices. Cancer This paper would not have been possible without the support of Ms. Manju Jain and Mr.Krishnan, who had helped with the Google forms early in the pandemic, all the physicians who submitted their data to the InPOG registry despite their busy schedules, and the relentless work of all the healthcare workers who continued to deliver care for children with cancer during the pandemic. My sincere thanks to Ms. Manjula Murugesan, who helped collate all the data, and our biostatistician Mr. Balasubramaniam for the data analysis.